Artiva Biotherapeutics, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Artiva Biotherapeutics is a clinical-stage biopharmaceutical company developing allogeneic natural killer (NK) cell and CAR-NK cell therapies for autoimmune diseases and cancer, using donor-derived cell lines designed to be administered off-the-shelf without prior chemotherapy conditioning in some programs.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Aslan FredChief Executive Officer | Sell | $169K | 23,463at $7.20 | Oct 6, 2026 |
| Bush JenniferCOO, CLO, Compliance Officer | Sell | $57K | 8,370at $6.84 | Oct 5, 2026 |
| Aslan FredChief Executive Officer | Sell | $422K | 61,696at $6.84 | Oct 5, 2026 |
| Banerjee SubhashisChief Medical Officer | Sell | $8K | 1,099at $6.84 | Oct 5, 2026 |
| Horan ChristopherChief Tech Operations Officer | Sell | $71K | 10,340at $6.84 | Oct 5, 2026 |
| Banerjee SubhashisChief Medical Officer | Sell | $99K | 8,222at $12.01 | Aug 27, 2026 |
| Banerjee SubhashisChief Medical Officer | Sell | $5K | 429at $12.00 | Aug 18, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ARTV activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.